西南医科大学学报2025，Vol.48Issue(2)：129-134,6.DOI:10.3969/j.issn.2096-3351.2025.02.004
成人复发/难治性费城染色体阳性急性淋巴细胞白血病研究进展
Advances in Adult Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
摘要
Abstract
Philadelphia chromosome-positive(Ph+)acute lymphoblastic leukemia(ALL)accounts for about a quarter of ALL cases in adults.The disease progresses rapidly,with a low response rate to standard chemotherapy and a high recurrence rate.The remission rate has been significantly improved after the addition of tyrosine kinase inhibitors(TKI)to the treatment regimen,but the relapse rate is still high.The overall survival rate of adult relapsed patients is only 4 to 6 months.More effective and safe treatment options are urgently needed for relapsed or refractory Ph+ALL.In recent years,the third-generation TKI,CAR-T therapy,monoclo-nal targeted therapy,and hematopoietic stem cell transplantation have shown good therapeutic effects in the treatment of relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia(R/R Ph+ALL).In this article,we reviewed and discussed the latest advances in the treatment of R/R Ph+ALL.关键词
急性淋巴细胞白血病/费城染色体阳性/酪氨酸激酶抑制剂/嵌合抗原受体T细胞免疫疗法/造血干细胞移植/单克隆抗体治疗Key words
Acute lymphoblastic leukemia/Philadelphia chromosome positive/Tyrosine kinase inhibitors/Chimeric antigen receptor T-cell therapy/Hematopoietic stem cell transplantation/Monoclonal antibody therapy分类
临床医学引用本文复制引用
刘倩,邢宏运..成人复发/难治性费城染色体阳性急性淋巴细胞白血病研究进展[J].西南医科大学学报,2025,48(2):129-134,6.基金项目
四川省科技厅科技计划项目(2022YFS0622-B3) （2022YFS0622-B3）
